Stockscreener 앱 받기
11.53
3.76%
-0.45
시장 영업 전:
11.85
0.32
+2.78%
Neuropace Inc 주식(NPCE)의 최신 뉴스
JPMorgan Chase & Co. Purchases 52,829 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Nantahala Capital Management LLC Sells 45,817 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Study: NeuroPace’s Technology Can Help Reduce Epileptic Seizures - Medical Product Outsourcing
28,547 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Purchased by Walleye Capital LLC - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Shares Acquired by JPMorgan Chase & Co. - Defense World
Retail investors who hold 34% of NeuroPace, Inc. (NASDAQ:NPCE) gained 10%, institutions profited as well - simplywall.st
Geode Capital Management LLC Has $3.62 Million Stock Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Rises By 45.8% - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Growth in Short Interest - Defense World
NeuroPace Inc (NPCE) Trading Down 3.19% on Apr 15 - GuruFocus
NeuroPace expects minimal tariff impact, maintains guidance By Investing.com - Investing.com South Africa
NeuroPace expects minimal impact of tariffs on its operations and financial results - MSN
Neuropace Provides Update On Tariff Status - marketscreener.com
NeuroPace Reports 'Minimal impact' From Trump Tariffs - marketscreener.com
NeuroPace Expects Minimal Impact from Trade Tariffs - TipRanks
NeuroPace expects minimal tariff impact, maintains guidance - Investing.com Australia
NeuroPace Provides Update on Tariff Status - The Manila Times
US Manufacturing Shield: NeuroPace Dodges Tariff Headwinds as Peers Struggle - Stock Titan
NeuroPace stock target cut to $17 by Cantor Fitzgerald - Investing.com Australia
Contrasting DIH Holding US (NASDAQ:DHAI) & NeuroPace (NASDAQ:NPCE) - Defense World
What is Leerink Partnrs' Forecast for NeuroPace Q1 Earnings? - MarketBeat
Cantor Fitzgerald cuts NeuroPace stock target to $17 By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts NeuroPace stock target to $17 - Investing.com
NeuroPace reports 82% seizure reduction in epilepsy study By Investing.com - Investing.com Australia
NeuroPace Reports Data From 3-year Post-Approval Study Of RNS System In Focal Epilepsy - Nasdaq
NeuroPace reports 82% seizure reduction in epilepsy study - Investing.com
NeuroPace announces data from long-term post-approval study of RNS System - TipRanks
NeuroPace Announces Data From a Long-Term Post-Approval - GlobeNewswire
Q1 Earnings Estimate for NeuroPace Issued By Leerink Partnrs - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Sees Large Growth in Short Interest - MarketBeat
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting - The Manila Times
Breakthrough Results: NeuroPace's Brain-Responsive Epilepsy Treatment Shows 3-Year Outcomes - Stock Titan
NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidance - MSN
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook By Investing.com - Investing.com Canada
NeuroPace to End Stereo EEG Distribution Accord; 2025 Revenue Guidance Affirmed - MarketScreener
NeuroPace to terminate distribution relationship for Seeg products - TipRanks
NeuroPace Shifts Focus to Core RNS System - TipRanks
Neuropace Inc Maintaining 2025 Revenue Guidance - MarketScreener
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook - Investing.com
NeuroPace Announces Refocusing of Product Portfolio - The Manila Times
11.62%
0.20%
자본화:
|
볼륨(24시간):